A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. 2007

J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
Division of Infectious Diseases, University Hospitals of Geneva, 24 Rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland. jorge.garbino@hcuge.ch

BACKGROUND Presumptive antimicrobial therapy is an important aspect of the management of intra-abdominal infections. Together with surgery, antimicrobial combinations are still widely used to achieve the required spectrum of activity. The aim of this study was to evaluate the efficacy of parenteral cefepime + metronidazole vs imipenem-cilastatin for the treatment of intra-abdominal infections in adult patients. METHODS Patients with a clinically confirmed diagnosis of intra-abdominal infection were randomized to one of two treatment regimens: cefepime 2 g iv/12 h plus metronidazole 500 mg/8 h or imipenem-cilastatin 500 mg iv/6 h. The primary measure of clinical response was the decline of pre-treatment signs and symptoms of infection. The duration of follow-up was 30 days. Treatment failure was defined as either a lack of improvement or a worsening of pre-treatment signs and symptoms of infection. Surgical management of the infection was determined by the surgeon-in-charge. RESULTS Of the 122 intended-to-treat patients included in the study, 60 patients (33 men) were randomized to cefepime + metronidazole and 61 (27 men) to imipenem-cilastatin. Cefepime + metronidazole treatment was successful in 52 (87%) patients and imipenem-cilastatin in 44 (72%) patients (p = 0.004). Microbiological eradication was established in similar proportions in both groups (cefepime + metronidazole, 43; imipenem-cilastatin, 38). CONCLUSIONS Further studies are warranted to confirm the better results with the cefepime + metronidazole regimen for the treatment of intra-abdominal infections.

UI MeSH Term Description Entries
D008297 Male Males
D008795 Metronidazole A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. 2-Methyl-5-nitroimidazole-1-ethanol,Bayer 5360,Clont,Danizol,Flagyl,Gineflavir,Metric,MetroGel,Metrodzhil,Metrogyl,Metronidazole Hydrochloride,Metronidazole Monohydrochloride,Metronidazole Phosphate,Metronidazole Phosphoester,Satric,Trichazol,Trichopol,Trivazol,Vagilen,2 Methyl 5 nitroimidazole 1 ethanol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D006785 Hospitals, University Hospitals maintained by a university for the teaching of medical students, postgraduate training programs, and clinical research. University Hospitals
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
December 1997, Archives of surgery (Chicago, Ill. : 1960),
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
January 2004, Surgical infections,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
November 1999, PharmacoEconomics,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
January 1996, Scandinavian journal of infectious diseases,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
September 1993, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
January 1995, The Journal of antimicrobial chemotherapy,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
March 1993, Surgery, gynecology & obstetrics,
J Garbino, and P Villiger, and A Caviezel, and R Matulionyte, and I Uckay, and P Morel, and D Lew
December 1992, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!